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Abstract
Breast Cancer (BC) is the most common cancer and the second most cause of death
among women. Mutations in BRCA1 and BRCA2 genes confer high susceptibility to
both breast and ovarian cancer. However, data on the prevalence of the BRCA1/2
mutations among breast and ovarian cancer patients is limited. The genetic component
of breast cancer in UAE is largely unknown and no study has evaluated the BRCA
mutations status in breast and ovarian cancer patients in UAE population. This
retrospective study aimed to establish mutation frequencies of the BRCA genes in
breast and ovarian cancer patients from Northern Emirates and sought to examine
potential association of BRCA carriers and Triple- Negative Breast Cancer (TNBC).
The study population included patients who underwent BRCA genetic testing at Sheikh
Khalifa Specialty Hospital (SKSH) to determine hereditary breast/ovarian cancer.
Mutations in BRCA1 and BRCA2 were analyzed by Sanger sequencing or next
generation sequencing (NGS) along with Multiple Ligation Probe Amplification
(MLPA).
Among 262 patients, 224 (85.5%) had no mutation. BRCA mutations were identified
in 38 patients (14.5%). BRCA1 and BRCA2 mutations were detected in 6.9% and 7.6%
of the patients, respectively. Variant of unknown significance in BRCA1 was found in
0.4% of patients (one patient). TNBC accounted for 22% of all patients with Breast
Cancer (BC) who underwent immunohistochemistry (28/127). Importantly, one novel
BRCA1 mutation: c. (80+1_81-1) _ (441+1_442-1) dup in exons 3,5,6,7 was observed
in one patient with ovarian cancer who showed positive family history and age ≤ 45.
Moreover, two novel deletion mutations were identified in the BRCA2 gene. One
deletion in exon 5 in ovarian cancer patient who showed positive family history and
age ≤ 45. The second was a deletion in exons 10-13 observed in male patient with
breast cancer with age ≤ 45. The current study results will help to establish the spectra
of BRCA mutations and risks associated with breast and ovarian cancer in UAE
patients.
Keywords: UAE, Hereditary, Breast cancer, Ovarian cancer, BRCA1, BRCA2, MLPA,
NGS, TNBC.
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)Title and Abstract (in Arabic

ﻧﺴﺒﺔ اﻧﺘﺸﺎر اﻟﻄﻔﺮات اﻟﺠﯿﻨﯿﺔ  BRCA1و  BRCA2ﺑﯿﻦ ﻣﺮﺿﻰ ﺳﺮطﺎن اﻟﺜﺪي
واﻟﻤﺒﯿﺾ ﻓﻲ اﻹﻣﺎرات اﻟﺸﻤﺎﻟﯿﺔ
اﻟﻤﻠﺨﺺ

ﯾﻌﺘﺒﺮ ﺳﺮطﺎن اﻟﺜﺪي أﻛﺜﺮ أﻧﻮاع اﻟﺴﺮطﺎن ﺷﯿﻮﻋﺎ ٌ و ﺛﺎﻧﻲ أﺣﺪ أﺳﺒﺎب اﻟﻮﻓﺎة ﺑﯿﻦ اﻟﻨﺴﺎء.
ﺗﻤﻨﺢ اﻟﻄﻔﺮات ﻓﻲ ﺟﯿﻨﺎت  BRCA1و  BRCA2ﻗﺎﺑﻠﯿﺔ ﻋﺎﻟﯿﺔ ﻟﻺﺻﺎﺑﺔ ﺑﺴﺮطﺎن اﻟﺜﺪي واﻟﻤﺒﯿﺾ.
و ﻣﻊ ذﻟﻚ ،ﻓﺈن اﻟﺒﯿﺎﻧﺎت اﻟﻤﺘﻌﻠﻘﺔ ﺑﻨﺴﺒﺔ إﻧﺘﺸﺎر طﻔﺮات  BRCA1/2ﻓﻲ ﻣﺮﺿﻰ ﺳﺮطﺎن اﻟﺜﺪي و
ﺳﺮطﺎن اﻟﻤﺒﯿﺾ ﻣﺤﺪودة .ﯾﻌﺘﺒﺮ اﻟﺘﻜﻮﯾﻦ اﻟﺠﯿﻨﻲ ﻟﺴﺮطﺎن اﻟﺜﺪي اﻟﻰ ﺣﺪ ﻛﺒﯿﺮ ﻏﯿﺮ ﻣﻌﺮوف و ﻟﻢ
ﺗﻘﻢ أي دراﺳﺔ ﺑﺘﻘﯿﯿﻢ ﺣﺎﻟﺔ طﻔﺮات ﺳﺮطﺎن اﻟﺜﺪي  BRCAﻟﺪى ﻣﺮﺿﻰ ﺳﺮطﺎن اﻟﺜﺪي و اﻟﻤﺒﯿﺾ
ﻓﻲ دوﻟﺔ اﻻﻣﺎرات اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة .ﺗﮭﺪف ھﺬه اﻟﺪراﺳﺔ إﻟﻰ ﺗﺤﺪﯾﺪ ﻣﻌﺪل إﻧﺘﺸﺎر اﻟﻄﻔﺮات اﻟﻮراﺛﯿﺔ
ﻓﻲ ﺟﯿﻨﺎت  BRCAﻟﺪى ﻣﺮﺿﻰ ﺳﺮطﺎن اﻟﺜﺪي واﻟﻤﺒﯿﺾ ﻣﻦ اﻻﻣﺎرات اﻟﺸﻤﺎﻟﯿﺔ ،ﻛﻤﺎ ﺳﻌﺖ إﻟﻰ
ﻓﺤﺺ اﻟﻌﻼﻗﺔ اﻟﻤﺤﺘﻤﻠﺔ ﺑﯿﻦ ﺣﺎﻣﻠﯿﻦ ﺳﺮطﺎن اﻟﺜﺪي  BRCAو ﺳﺮطﺎن اﻟﺜﻼﺛﻲ اﻟﺴﻠﺒﻲ ).(TNBC
ﺷﻤﻠﺖ اﻟﺪراﺳﺔ ﻋﻠﻰ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﺧﻀﻐﻮا ﻟﻼﺧﺘﺒﺎر اﻟﺠﯿﻨﻲ  BRCAﻓﻲ ﻣﺴﺘﺸﻔﻰ اﻟﺸﯿﺦ ﺧﻠﯿﻔﺔ
اﻟﺘﺨﺼﺼﻲ ) (SKSHﻟﺘﺤﺪﯾﺪ اﻻﺻﺎﺑﺔ ﺑﺴﺮطﺎن اﻟﺜﺪي  /اﻟﻤﺒﯿﺾ اﻟﻮراﺛﻲ .ﺗﻢ ﺗﺤﻠﯿﻞ اﻟﻄﻔﺮات
اﻟﻮراﺛﯿﺔ ﻓﻲ ﺟﯿﻨﺎت  BRCA1و  BRCA2ﻋﻦ طﺮﯾﻖ إﺟﺮاء ﻓﺤﺺ ﻣﻌﺮﻓﺔ اﻟﺘﺴﻠﺴﻞ اﻟﺠﯿﻨﻲ
 Sangerأو ﺗﻘﻨﯿﺔ اﻟﺠﯿﻞ اﻟﺠﺪﯾﺪ ﻟﺘﺤﺪﯾﺪ اﻟﺘﺴﻠﺴﻞ اﻟﺠﯿﻨﻲ ) (NGSﺑﻺﺿﺎﻓﺔ إﻟﻰ ﻓﺤﺺ اﻟﺘﻀﺨﯿﻢ
ﻣﺴﺒﺎر اﻟﺮﺑﻂ اﻟﻤﺘﻌﺪد ).(MLPA
ﻣﻦ إﺟﻤﺎﻟﻲ ﻋﺪد  262ﻣﺮﯾﺾ ،ﻟﻢ ﯾﻜﻦ ﻟﺪى  224ﻣﺮﯾﺾ طﻔﺮة ﺟﯿﻨﯿﺔ ﻓﻲ BRCA
) ، (%85.5ﺑﯿﻨﻤﺎ ﺗﻢ ﺗﺤﺪﯾﺪ طﻔﺮات  BRCAﻟﺪى  38ﻣﺮﯾﻀﺎ ٌ ) . (%14.5ﺣﯿﺚ ﺗﻢ اﻟﻌﺜﻮر ﻋﻠﻰ
طﻔﺮات  BRCA1و  BRCA2ﺑﻨﺴﺒﺔ  %6.9و  %7.6ﻣﻦ اﻟﻤﺮﺿﻰ ﻋﻠﻰ اﻟﺘﻮاﻟﻲ .ﻛﻤﺎ ﺗﻢ اﻟﻌﺜﻮر
ﻋﻠﻰ طﻔﺮات ﻣﺠﮭﻮﻟﺔ اﻻھﻤﯿﺔ ﻓﻲ  BRCA1ﺑﻨﺴﺒﺔ  %0.4ﻣﻦ اﻟﻤﺮﺿﻰ )ﻣﺮﯾﺾ واﺣﺪ( .ﯾﻤﺜﻞ
ﺳﺮطﺎن اﻟﺜﻼﺛﻲ اﻟﺴﻠﺒﻲ ) (TNBCﻧﺴﺒﺔ  %22ﻣﻦ إﺟﻤﺎﻟﻲ ﻋﺪد اﻟﻤﺮﺿﻰ ) (127/28اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن
ﻣﻦ

ﺳﺮطﺎن

اﻟﺜﺪي

و

اﻟﺬﯾﻦ

ﺧﻀﻐﻮا

ﻟﻔﺤﻮﺻﺎت

اﻟﻜﯿﻤﯿﺎء

اﻟﻨﺴﯿﺠﯿﺔ

اﻟﻤﻨﺎﻋﯿﺔ

).(Immunohistochemistry
اﻟﺠﺪﯾﺮ ﺑﺎﻟﺬﻛﺮ ھﻮ اﻟﻌﺜﻮر ﻋﻠﻰ طﻔﺮة ﺟﺪﯾﺪة ﻓﻲ ﺟﯿﻦ c. (80+1_81-1) _ ) BRCA1
 ،((441+1_442-1) dupوھﻮ ﺣﺪوث ﺗﻜﺮار ﻓﻲ اﻛﺴﻮن  exons 3,5,6,7ﻓﻲ ﺣﺎﻟﺔ واﺣﺪة
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ﻟﻤﺮﯾﻀﺔ ﻣﺼﺎﺑﺔ ﺑﺴﺮطﺎن اﻟﻤﺒﯿﺾ ،ﻟﻢ ﺗﺘﺠﺎوزﻋﻤﺮ  45ﺳﻨﺔ وﻟﺪﯾﮭﺎ ﺗﺎرﯾﺦ ﻋﺎﺋﻠﻲ .ﻋﻼوة ﻋﻠﻰ ذﻟﻚ،
ﺗﻢ اﻛﺘﺸﺎف طﻔﺮﺗﯿﻦ ﺟﺪﯾﺪﺗﯿﻦ ﻟﻠﺤﺬف ﻓﻲ ﺟﯿﻦ  ،BRCA2اﺣﺪھﻤﺎ ﺣﺬف اﻛﺴﻮن  5 exonﻓﻲ ﺣﺎﻟﺔ
ﻟﻤﺮﯾﻀﺔ ﻟﻢ ﺗﺘﺠﺎوز ال  45ﺳﻨﺔ ﻣﺼﺎﺑﺔ ﺑﺴﺮطﺎن اﻟﻤﺒﯿﺾ و ﻟﺪﯾﮭﺎ ﺗﺎرﯾﺦ ﻋﺎﺋﻠﻲ .و اﻟﺤﺎﻟﺔ اﻟﺜﺎﻧﯿﺔ ھﻮ
ﺣﺬف ﻓﻲ اﻛﺴﻮﻧﺎت  13-10 exonsﻟﻮﺣﻈﺖ ﻓﻲ ﻣﺮﯾﺾ ذﻛﺮ ﻣﺼﺎب ﺑﺴﺮطﺎن اﻟﺜﺪي ،ﻟﻢ ﯾﺘﺠﺎوز
ال 45ﺳﻨﺔ .ھﺬه اﻟﻨﺘﺎﺋﺞ ﺳﺘﺴﺎﻋﺪ ﻓﻲ ﺗﺄﺳﯿﺲ ﻣﺤﺘﻮى واﺿﺢ ﻟﻠﻄﻔﺮات اﻟﺠﯿﻨﯿﺔ  BRCAو اﻟﻤﺨﺎطﺮ
اﻟﻤﺮﺗﺒﻄﺔ ﺑﺴﺮطﺎن اﻟﺜﺪي واﻟﻤﺒﯿﺾ ﻟﺪى ﻣﺮﺿﻰ ﺷﻤﺎل دوﻟﺔ اﻻﻣﺎرات اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة.

ﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ اﻟﺮﺋﯿﺴﯿﺔ :دوﻟﺔ اﻻﻣﺎرات اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة ،ﺳﺮطﺎن اﻟﺜﺪي واﻟﻤﺒﯿﺾ اﻟﻮراﺛﻲ،
ﺳﺮطﺎن اﻟﺜﺪي ﺛﻼﺛﻲ اﻟﺴﻠﺒﯿﺔ ،ﻓﺤﺺ اﻟﺘﺴﻠﺴﻞ اﻟﺠﯿﻨﻲ ،ﻓﺤﺺ اﻟﺘﺴﻠﺴﻞ اﻟﺠﯿﻨﻲ اﻟﺘﺎﻟﻲ ،ﻓﺤﺺ
ﺗﻀﺨﯿﻢ اﻟﻜﺸﻒ ذو اﻟﺮﺑﻂ اﻟﻤﺴﺘﻘﻞ اﻟﻤﺘﻌﺪد.
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Chapter 1: Introduction
1.1 Cancer
Cancer is uncontrolled cell division that can occur in any place of the body. In
normal cell division, an accurate genome duplication will occur to ensure that the two
daughter cells will have the same genetic material as their parent cell. Any failure to
achieve this purpose will develop a genomic instability, which generates random
mutations including chromosomal rearrangements and different forms of genome
alterations. The accumulation of these genetic alterations may varies between different
subgroups of cells and leads to form the heterogeneity of cancer [1-2].
Cancer cells are distinct from their normal counterparts through six essential
biological features. In 2002, these biological features were first introduced and defined
as a cancer hallmarks which includes sustaining proliferative signaling, evading
growth suppressors (antigrowth), resisting cell death (apoptosis), enabling replicative
immortality, inducing angiogenesis and activating invasion and metastasis (Figure 1).
Four additional hallmarks of cancer were introduced in 2011, including deregulating
cellular energetics, avoiding immune destruction, genomic instability and mutation
and tumor promoting inflammation [3].
The pathogenesis of cancer is multifactorial, as for many other malignancies, involving
interactions between different life style and genetic characteristics. Cancer remains
one of the most health burden disease worldwide. The incidence of cancer has been
rapidly increased resulting in over 8.7 million deaths [4]. Based on 2018 GLOBOCAN
statistics, the total number of cancer new cases was around 18 million while the death
cases was 9 million in 2018 (Figure 1) [5].

2

Figure 1: Global cancer statistics 2018 (GLOBOCAN) [5].
In the United Arab Emirates (UAE), the burden of cancer in 2010 was high and
ranked the third leading cause of non-communicable diseases (NCD)-related mortality
after cardiovascular and injury [6]. The GLOBOCAN data from 2018 shows that the
cancer incidence rate reached 135.5 per 100,000 people and the mortality rate was 54.7
per 100,000 people in UAE [5].
1.1.1 Breast Cancer
Breast cancer is the most prevalent type of cancer among women worldwide
with 25.4% of total cancer cases in 2018 [7]. It considered as serious threat to the
global development with estimated 1,384,155 new cases and approximately 459,000
deaths cases. It has been estimated that one every eight women will develop breast
cancer during her life [8].
Breast cancer is not a single disease but a complex multifactorial disease
resulting from interactions between a number of different environmental, lifestyle,
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hormonal, and genetic factors. There are three most common diagnostics markers in
clinical management of BC patients which are human epidermal growth factor 2
(HER-2), estrogen (ER), and progesterone (PR). BC cell expression of these receptors
has an impact in disease progression and also in the therapeutic management. The
majority of BCs are sporadic, which means it develops from damage to a person's
genes that occurs by chance after they are born. There is no risk of the person passing
this gene on to their children. However, the familial susceptibility to BC accounts for
more than 25% of all BCs [9].
BC is the most dominant cancer among women in Arab countries [10]. Women
in Arab world are diagnosed with breast cancer at more advanced stages, and the
incidence rate has increased over the past three decades [11]. According to American
Cancer Society, prediction of new cases of breast cancer in women will reach to about
3.2 million in 2050 [12]. These statistics demonstrate the vastness of breast cancer
incidence and its effect on societies worldwide.
The Health Authority of Abu Dhabi (HAAD) reported that the prevalence of
breast cancer among all cancers diagnosed in Abu Dhabi reached 20.3% in 2014, with
an associated mortality rate of 12.2%, making breast cancer the most incident in that
Emirate [13]. Of all cancer cases, breast cancer in women from the GCC countries is
the most common cancer type. It was reported by the Gulf Center for Cancer
Registration that annually, for every 100,000 female there are 53.4 cases of breast
cancer in Bahrain, 22.8 cases in the United Arab Emirates, 17.5 cases in Saudi Arabia,
48.2 cases in Qatar, and 46.6 cases in Kuwait [14]. However, the effect of geographical
and ethnical differences in breast cancer incidence signs the impact of environmental
conditions and the way of life (Figure 2) [15].
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Figure 2: Breast cancer prevalence around the world [5].
1.1.2 Ovarian Cancer
Worldwide, ovarian cancer (OC) is the seventh most common cancer and the
eighth leading cause of cancer-related mortality in females, contributing nearly 4% of
the total number of new cases diagnosed in 2018 [7]. A number of clinical features are
considered to affect progression-free-survival and overall survival rates in ovarian
cancer, which includes disease grade, stage and surgical outcome. There are five main
histologically defined subtypes of OC which are high grade serous, endometrioid, clear
cell, low grade serous and mucinous OC serous and mucinous OC. As the majority of
OC is high grade serous, the studies focused on this subgroup more than others [16].
Ovarian cancer, like other types of cancer, may occur spontaneously, and mostly
developed due to genetic predisposition involving dysfunctional of dominant genes
[17]. However, more than 23% of all ovarian cancer cases are thought to be hereditary
[18]. Also, it was reported that in ovarian cancer relatives, the risk of breast cancer is
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increased and vice versa [19]. In Saudi Arabia, the OC accounted for 2.9% of all
cancers, whereas in western population it accounted for 3.4%. The median age of OC
Saudi population (55 years) and Middle East Epithelial OC population (50 years) were
lower than western population (65 years), which could influence the genetic
predisposition factors in their ethnicity. Therefore, determination such genetic
predisposition will make efficient early diagnosis and cancer prevention process [20].
1.2 Genetic Mutation and Hereditary Breast and/or Ovarian Cancer (HBOC)
In human, genes are located on 23 pairs of chromosomes. During the process
of cancer development, malignant transformation is known to involve genetic and
epigenetic changes that lead to uncontrolled cellular proliferation and/or abnormal
programmed cell death (apoptosis). These cellular abnormalities resulted through
accumulation of mutations that are frequently associated with molecular abnormalities
in certain types of genes, such as proto-oncogenes and tumor-suppressor genes [8, 10].
These mutations can result from genetic predisposition and/or exposure to several risk
factors such as physical inactivity and sedentary lifestyles, the overconsumption of
high-caloric and poorly-nutritive meals, an increase in obesity rates, an increase in
smoking prevalence, elevated air pollutant levels, different forms of ionizing
radiations, and synthetic chemicals. Mutations are either inherited from a parent
(germline) or acquired affecting only the cells that grow from the mutated cell
(somatic). Somatic mutation may determine the phenotype of a particular cancer and
maybe of clinical value in determining cancer prognosis. However, only germline
mutations can predetermine an individual’s risk of developing cancer. Among all
cancer types, only about 5-10% are thought to be related to an inherited gene change
[21].
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Hereditary Breast and/or Ovarian Cancer (HBOC) syndrome is an inherited
genetic disorder with high level of risk compared to the normal breast and ovarian
cancer in related family members [17]. Approximately 5-10% of breast cancer cases
[18] and about 18% of ovarian cancer cases [22] are due to genetic mutation which is
thought to be hereditary.
1.2.1 BRCA1/2 Genes
Minority of breast cancers can show dominant gene mutations. The most
common gene mutations are those affecting the Breast CAncer 1 (BRCA1) and BReast
CAncer 2 (BRCA2) genes [8]. BRCA genes, important tumor suppressor genes, are
involved in DNA damage repair and recombination, cell-cycle checkpoint control,
apoptosis and transcriptional regulation [23]. BRCA 1 and 2 genes were reported and
identified as breast cancer susceptibility genes for the first time in 1994 and 1995
respectively. Since the time of their discovery, the number of studies reporting the
frequency of mutations in these genes in high-risk breast and breast-ovarian cancer
families have been increased largely. The breast cancer susceptibility gene BRCA1 is
expressed in several tissues including breast and ovary. BRCA1 gene (Figure 3) is a
large gene extend to about 100 kb of genomic DNA. It consists of 24 exons, the first
and fourth exons are non-coding [24]. Eleventh exon is the largest exon providing
more than 60% of the whole coding sequence of BRCA1 gene [25]. The final product
of the protein composed of 1863 amino acids, produce about 220 kd nuclear protein.
This BRCA1 gene product contains a protein motif, a Ring Finger domain near the
amino acid terminus and a conserved acidic carboxyl terminus that functions in
transcriptional co-activation. It was proven that BRCA1 protein plays a crucial part in
the DNA repair process. RAD51 gene, encodes a protein called RAD51, which is
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important in the stability of the genome and essential for the repair of damaged DNA.
BRCA1 protein reacts with RAD51 protein during homologous recombination and
double strand break repair [23]. The BRCA2 gene (Figure 3) is larger compared to
BRCA1, composed of 27 exons, where one is non-coding. It codes for a protein of 3418
amino acids that produce a nuclear protein of 380 kd. BRCA2 gene has a different
structure than BRCA1 and the protein lacks a well-defined functional domain. Also,
the BRCA2 protein reacts with RAD51 protein and during this cross interaction with
RAD51, both BRCA1 and BRCA2 interrelate at sites of DNA synthesis after the
induction of DNA damage. Thus, the proteins made by BRCA1 and BRCA2 genes are
both essential for repairing damaged DNA and any changes in these genes may lead
to hereditary predisposition to breast and ovarian cancer [24].

Figure 3: BRCA1 and BRCA2 genes [26].
1.2.2 BRCA1/2 Genes Mutations
Mutations in BRCA genes induce defective DNA repair mechanisms, which
are associated with the risk of developing breast and/or ovarian cancers. Changes in
BRCA genes are spread all over the entire gene. Different mutations have been reported
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that exceeds 600 and 400 in BRCA1 and BRCA2, respectively. Most types of gene
mutations considered to be risky and disease-causing that produce a defective and nonfunctional protein. There are several forms of mutations reported in BRCA genes such
as frame shift mutation when either deletion or insertion (indels) of one or more
nucleotides resulting in missing or non-functional product, nonsense mutation when
change in one nucleotides produce a stop codon that terminate the protein, or splice
site alternations that affect the DNA identity and results in abnormal protein [24].
About 12% of women in the general population will develop breast cancer sometime
during their lives and about 1.4% of women in the general population will develop
ovarian cancer sometime during their lives. One in 400 to 1,000 persons in the overall
population are expected to have a germline mutation in BRCA1 and BRCA2 genes that
passed down through their families known as autosomal dominant predisposing genes
[27]. Some studies showed that a mutation that found towards the 5’-end of BRCA1
gene tends to develop ovarian cancer whereas mutation towards the 3’-end seems to
develop breast cancer which means that there is a possible relation between the
mutation site and the corresponding phenotype [25]. Inherited deleterious mutations
in the BRCA1 or the BRCA2 genes are associated with an increased risk of developing
breast and/or ovarian cancer in both woman and men. Women with an inherited
BRCA1 mutation have a lifetime risk of 65-80% of developing breast cancer and 3762% of developing ovarian cancer, while BRCA2 carriers have a lifetime risk of 4585% for breast cancer and 11-23% for ovarian cancer. There is an increased risk of
developing several other cancers in addition to breast and ovarian cancer among BRCA
carriers. BRCA1 mutations may increase a woman’s risk of developing fallopian tube
cancer and peritoneal cancer. Men with pathogenic BRCA1 or BRCA2 mutations have
a higher risk of prostate cancer (5-25%), and breast cancer among men with BRCA2
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mutations (6%). Men and woman with BRCA1 and BRCA2 mutations maybe at
increased risk of pancreatic cancer, stomach, and head and neck. Together, BRCA1
and BRCA2 mutations cause about 20-25% of hereditary breast cancers. In addition,
mutations in BRCA1 and BRCA2 account for around 15% of ovarian cancers overall.
Studies on BRCA1 mutation occurrence suggested that nearly half of the families at
high risk for breast cancer carried BRCA1 mutation. However, other analysis suggests
that the actual incidence of BRCA1 in high risk families (>3 cases of breast and/or
ovarian cancer) might be as low as 12.8% to 16%. It has been observed that large
variation in the prevalence of BRCA1 mutations in high risk families of different
countries more common than the prevalence of BRCA2 mutations [19, 25, 28, 29].
1.3 Triple Negative Breast Cancer (TNBC)
Triple-negative breast cancer is an aggressive subtype of breast cancer with a
higher risk of both local and distant recurrence and poor overall prognosis and it
accounts for about 10-20% of all cases of breast cancer. TNBC is characterized by a
lack of the expression of estrogen (ER), progesterone (PR) and human epidermal
growth factor 2 receptors (HER2/neu), thus, no validated molecular targets for
treatment are available .TNBC shows an estimated range between 10% and 20% of all
breast cancers and having a family history of TNBC and/or BRCA mutations may
increase the possibility of having TNBC [30]. It has been unclear how much BRCA1/2
mutation frequency may influence the expression of ER, PR, and HER2/neu [31]. With
the development of targeted therapies for breast cancer patients, designation of
treatment regimens has become more specific, and breast cancer patients with BRCA
mutations should be treated differently from the patients without BRCA mutations. The
exact relationship between BRCA status and TNBC is still under investigation.
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1.4 Prevalence of BRCA1/2 Gene Mutations
The overall prevalence of pathogenic BRCA1/2 gene mutations is low in the
general population (~0.2-0.3%). This prevalence is increased to approximately 3% in
women with breast cancer, 6% in women with breast cancer onset at young age (before
the age of 40), and higher prevalence is associated with a positive family history of
breast or ovarian cancer (20%) [32]. Although it has been demonstrated that the overall
prevalence of BRCA1 or BRCA2 oncogenic mutations may differ widely according to
the study populations, other studies conclude that mutation prevalence is similar across
diverse races and ethnicities [33-34].
1.4.1 Prevalence of BRCA1/2 Mutation in the World
Recent studies indicate that there is a significantly variation in the prevalence
of BRCA1 or BRCA2 mutations among ethnic groups and geographical areas.
Mutations in BRCA1 and BRCA2 are more common in certain racial/ethnic
populations. There are common mutations in specific population that have been
described among Ashkenazi Jews population [35] as well as patients of Spanish
ancestry and that due to common ancient ancestor [36]. Founder BRCA1 and BRCA2
mutations have also been found in several European populations in Austria, Slovenia,
Italy, France, Spain, Portugal, Belgium, the Netherlands (Holland), Germany, Czech
Republic, Slovakia, Hungary, Greece, Cyprus, Denmark, Sweden, Norway, Finland,
Iceland, the United Kingdom, Ireland, Poland, Latvia, Lithuania, Estonia, Belarus, and
Russia [36]. Prevalence of BRCA1 and BRCA2 mutations varied widely between key
clinical and demographic subgroups and across countries. Data from Table 1 were
adopted from Armstrong et al. [37], which summarizes the prevalence of both genes
mutation in several studies reported on BRCA mutation prevalence in patients with
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different stage of breast cancer and different hormone receptor status. The highest
germline mutation of BRCA was reported in the United States [37].
Table 1: Prevalence of Germline BRCA Mutation Internationally (Unselected for
Family History, Age, Sex, or Ethnicity) [37].
Country

Study
Reference
Sharma et
al. [60]
Couch et
al. [56]

United
States

Tung et al.
[61]
Bayraktar
et al. [62]
Vidula et
al. [63]

Spain

Australia

GonzalezRivera et
al. [64]
WongBrown et
al. [65]

Hormone
Receptor
status

%
BRC
A
1/2

Breast
Cancer
Stage

N at risk
of
mutation

Mixed

207

11.1

4.3

15.4

NR/unclear

1824

8.5

2.7

11.2

Stages I-III
Stages I-III

301
488

1.7
3.7

3.3
2.5

5
6.1

195

15

6

21

178

NA

NA

15.2

Stages IIIII

105

12.4

1.9

14.3

Mixed

439

5.9

3.4

9.3

NR/unclear

726

1

1.9

2.9

Metastatic

1462

1.4

2.9

4.3

Metastatic

407

0.7

2

2.7

%
BRCA
1

%
BRCA
2

TNBC
HR+/HER2Mixed

NR/unclear

Metastatic
BC

TNBC

Sardinia/
Italy

Palomba et
al. [66]

Germany

Fasching et
al. [67]

France

Meynard et
al. [68]

South
Korea

Kim et al.
[69]

NR/unclear

NR/unclear

471

1.5

1.5

3

Israel

Dagan et
al. [70]

Female,
Ashkenazi,
Early onset

Locally
advanced
BC

13

23.1

30.8

53.8

Mixed

Abbreviations: BC, breast cancer; BRCA, BC susceptibility gene; HER2-, human epidermal growth factor
receptor 2–negative; HR+, hormone receptor–positive; NR, not reported; TNBC, triple-negative BC.
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1.4.2 Prevalence of BRCA1/2 Mutations in the Arab Countries
The incidence and mortality of cancer in Arab countries is increasing rapidly
and this will obstruct human development and well-being. The most common cancer
among women in Arab countries was Breast cancer with 49.9% and Ovarian cancer
with 5% in 2012. WHO estimated that by 2030, there will be an increase of 1.8 fold in
cancer incidence in the Gulf States and the Eastern Mediterranean region [38]. The
number of cancer researches and publications from Arab region is considered low
compared to worldwide publications and this due to less number of researchers in this
field, the high cost of research and low research output [10]. This explains the rarity
of high quality data on BRCA mutations in Arab populations. Breast cancer is the first
leading cause of all cancer deaths among Arab females with approximately rate of 14
to 42% of all female cancers in Arab region [18]. According to Abdulrashid et al. [18]
it has been shown that HBOC patients in Arab countries have BRCA mutations and the
prevalence of BRCA2 mutations were more common (17%) than BRCA1 mutations
(11%) among the breast cancer patients in the Arab region [18].
1.4.3 Prevalence of BRCA1/2 Mutations in the Gulf Countries
There are six member countries of the Arabian Gulf Cooperation Council that are:
Saudi Arabia, Bahrain, Kuwait, Oman, Qatar and United Arab Emirates. Due to the
migration from Africa, the first Eurasian populations formed and found to be
genetically related to the original Arabs. In the GCC, populations are divided to genetic
subgroups, about 48.1% of GCC populations was expats because of recent migration
of migrant workers [14]. The fact of being descended from the same ancestors has led
to an increase in genetic diseases among GCC populations and these factors contribute
to a unique genetic makeup in their populations. According to Abulkhair et al. [27]
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prevalence of BRCA1 gene mutation (82.5% of mutations) in Saudi patients is more
than BRCA2 gene mutations [27]. In Oman, Kuwait and Bahrain, the knowledge about
the frequency of BRCA1/2 gene mutations among breast cancer patients is not yet
available. Although it was reported that Qatari breast cancer patients with BRCA1
mutations carriers were triple negative breast cancer [14]. Although patients with
hereditary breast and/or ovarian cancer (HBOC) in GCC countries have minimal
contributions to BRCA1/2 mutations, which is the most reported form of cancer in
Oman, there is a lack of data about the BRCA1/2 mutation role in breast cancer in the
region [14].
The current population structure of the UAE is diverse; a result of a high
percentage of expatriates (80-90%, residing in the country), compared to a relatively
small but diverse indigenous population admixed with immigrants from Yemen,
Oman, North Africa, Iran, Baluchistan, India, and other neighboring regions.
Approximately 11 million residents in the UAE, however, around 10% only are
Emirati citizens where endogamous marriage is common, making this segment of UAE
population relatively homogenous [39-40].
The knowledge about the prevalence and types of BRCA1 and BRCA2
mutations involved in breast and ovarian cancer patients in UAE is unavailable. Given
these considerations, this study aims to determine the prevalence of BRCA1 and
BRCA2 mutations in patients with breast and/or ovarian cancer; leading to better care
for patients in this region.
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This study was conducted on patients from northern region of UAE including
five emirates: Sharjah, Ajman, Ras Al Khaimah, Umm Al Qaiwain, and Fujairah.
About one third of the population live in the Northern Emirates (Figure 4) [42].

*Projected Population of each emirate in 2018 based on last known official Population Estimate and
Population Growth Rate.

Figure 4: United Arab Emirates map (Up) showing the northern regions of the emirates
and UAE population percent by emirate (Down) [41].
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1.5 Hypothesis
BRCA1 and 2 mutations contribute to the incidence of breast and ovarian
cancer among northern Emirates patients.
1.6 Objectives of the Study
The main aims of this study are to:
1- Estimate the frequency of BRCA1/2 genes mutations among cases of
breast and ovarian cancer in northern Emirates.
2- Determine the types of BRCA1/2 genes mutations associated with
breast and ovarian cancer patients diagnosed at the Oncology
Department, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah,
UAE.
3- Investigate the potential relationship between BRCA status and TNBC.
4- Identify possible novel BRCA1/2 mutations among UAE population.
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Chapter 2: Materials and Methods
2.1 Study Design
This retrospective study was conducted on 262 patients who underwent BRCA
genetic testing to determine hereditary breast/ovarian cancer. 262 unselected breast
and ovarian cancer patients, diagnosed at any age from July 2015 to August 2020, from
the Oncology Department, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, UAE.
In total, 262 patients were approached in this study during their out-patient visit to the
Oncology Department in the hospital. Before the test, all patients had been informed
about the implications of genetic testing, and interviewed in person for their family
history of cancer. The oncologist filled the genetic test request form with patient
information, onset of symptoms, familial history of cancer with specific reference to a
history of breast or ovarian cancer and family tree for at least three generation. Medical
records for all patients included in this study were reviewed retrospectively. This study
was approved by The Institutional Review Board (IRB) in Ministry of Health and
Prevention in Dubai, UAE (MOHAP/DXB-REC/AAA/No.111/2020).
2.2 Blood Collection and DNA Extraction
For each BRCA gene analysis test request, a blood sample was obtained from
each patient for DNA extraction. Approximately 6 mL of whole blood was collected
in sterile tubes containing EDTA from all subjects enrolled in this study. Genomic
DNA was extracted manually (following standard protocol) using the QIAamp Blood
Mini Kit from QIAGEN manufacturer. The purity and concentration of the extracted
DNA was assessed using Nanodrop 2000/2000c Spectrophotometer from

17
ThermoScientific. The ultimate concentration used was 25-50 ng/µL and the ratio of
(A260/A280) was not less than 1.8 to assure the good quality of DNA.
2.3 BRCA Genes Analysis
2.3.1 Sanger Sequencing
BRCA1/2 gene analysis is based on the Gold Standard Sanger Sequencing.
Human Genome build NCBI36 (BRCA1: Acc. nr: NM_007300, BRCA2:Acc. nr:
NM_000059), M13 tailed PCR primers were designed and optimized for 100%
coverage of the coding sequence of the BRCA1 and BRCA2 genes, including sections
of approximately 50 bp up- and downstream of each exon (24 exons for BRCA1 and
27 exons for BRCA2). All amplicons can be amplified and sequenced using one
universal set of PCR conditions.
For sequencing, PCR using EasySeq™ PCR Plates (Figure 5). 96 well-plate
containing dried down primer pairs in optimized concentrations, covering both BRCA
genes. Columns 11 and 12 contain all amplicons, in a total of 15 PCR multiplexes, to
be used as a No Template Control (NTC), to confirm all results are specific.
All primer sets have been optimized in concentration and design to be
compatible with key chemistries [42].
Cycle Sequencing is performed with universal sequencing primers: Forward
primers with -21M13 and reverse primers with M13Rev to enable cycle sequencing
with universal primers (Figure 6).
Raw data of sequencing is analyzed with reference sequence using software
(Sequencher v5).

Figure 5: EasySeq™ PCR plates for BRCA1/2 Sequencing [42].
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Figure 6: Forward primers with -21M13 and reverse primers with M13Rev.
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2.3.2 Next Generation Sequencing (NGS)
The Ion Torrent system (http://www.iontorrent.com) is unique among Next
Generation Sequencing technologies in that the detection for sequencing is not based
upon ﬂuorescent dyes but rather measuring the pH change as the result of the release
of a H + ion upon nucleotide incorporation using semiconductor technology (Ion
semiconductor sequencing). By sequentially adding nucleotides, the machine is able
to detect which nucleotide has been incorporated into the growing strand.
The Oncomine™ BRCA Research Assay consists of two pools of AmpliSeq™
oligonucleotide primers and associated reagents to generate amplicon libraries for
next-generation sequencing (NGS) on Ion Torrent™ platforms. The assay is designed
to provide sensitive and comprehensive sample amplification of all coding regions of
the human BRCA1 and BRCA2 genes and by using the Ion Chef™ System where the
library preparation is automated.
2.3.3 Multiple Ligation- dependent Probe Amplification Analysis (MLPA)
The MLPA protocol (MLPA®DNA protocol) was performed using the
instructions provided by the company http://www.mrc-holland.com. The MLPA assay
was performed using a set of probes for BRCA1 (P002-D1 probe mix), for BRCA2
(P045/CHEK2 probe mix) and the EK5 SALSA MLPA reagents kit purchased from
MRC-Holland (Amsterdam, The Netherlands). These probes were used to detect the
deletion or duplication of exons in the human BRCA1/BRCA2 genes in order to
determine genetic predisposition to hereditary breast and/or ovarian cancer. Briefly,
10 ng of genomic DNA in a volume of 5 μl was denatured for 5 min at 98°C, cooled
and hybridized with MLPA probes (1.5 μl/sample) in the presence of SALSA MLPA
buffer (1.5 μl/sample) for 16 h at 60°C. Ligation reaction was performed for 15 min at
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54°C by adding 32 μl of ligation mixture (3 μl SALSA Ligase buffers A and B,
respectively, 25 μl demineralized water, and 1 μl SALSA Ligase-65/sample) followed
by heating to 95°C for 5 min. PCR amplification of the ligation product was performed
according to the standard protocol. Briefly, 10 μl was added to the mixture consisting
of (7.5 μl demineralized water, 2 μl SALSA PCR primers and 0.5 μl SALSA
polymerase/sample) while the samples were left at 4°C or on ice. The samples were
pre-heated to 60°C for 30 s, followed by 35 cycles of 95°C for 30 s, 60°C for 30 s,
72°C for 1 min, and a final extension for 20 min at 72°C. From each PCR reaction, 0.7
μl product was mixed with 9 μl of Hidi Formamide (Applied Biosystems Foster City,
CA, USA) and 0.2 μl of GeneScan™ 500 LIZ™ dye Size Standard (Applied
Biosystems, Foster City, CA, USA) and all fragments were separated by capillary
electrophoresis on the ABI 3500XL Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA). Sequencer, SeqScape and GeneMarker, unique genotype analysis
software’s designed for mutation detection, were used in the analysis.
2.4 Immunohistochemistry
A total of 127 patients with invasive breast carcinoma who underwent
mastectomy were tested for ER, PR and the HER-2 status. Briefly, tissue samples from
each patient were fixed in 10% neutral buffered formalin and embedded in paraffin.
Sections were deparaffinized in xylene, rehydrated in a graded ethanol series, and
stained using a Benchmark XT (Roche, Basel, Switzerland). Immunohistochemical
analysis was carried out with the following monoclonal antibodies: anti-estrogen
receptor (clone SP1, commercially with appropriate dilution, Roche, Basel,
Switzerland), anti-progesterone receptor (clone 2E2, commercially with appropriate
dilution, Roche, Basel, Switzerland) and anti-HER-2 (clone 4B5, commercially with
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appropriate dilution, Roche, Basel, Switzerland). Staining was assessed according to
the ASCO/CAP guidelines.
2.5 Statistical Analysis
The data, either clinical or genetic findings, were statistically evaluated.
Statistical significance was performed to find the association between BRCA1 gene
mutation and other parameters using a two-sided significance level of 5% and 1%. The
statistical analysis was interpreted and analyzed using the SPSS software version 16
and Microsoft Excel Data Analysis Tool.
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Chapter 3: Results
3.1 Study Selection and Patient Characteristics
Total of 262 cases were tested for BRCA1/2 mutation analysis. Patient’s
clinical characteristics are presented in Table 2. The mean age at the time of diagnosis
was 46.5 years (range 21-90). 71 out of 262 patients (27%) had a positive family
history for hereditary breast and ovarian cancer.
Of total 262, 248 (94.7%) patients were females and 14 (5.3%) were males.
Total of 186 of the 262 patients (71%) diagnosed with breast cancer and 22/262 (8.4%)
had ovarian cancer. Patients and relatives of cancer patients from Emirates citizen were
the most common with total number 230 cases (87.8%), 10 cases from gulf countries
(3.8%), 13 from Arab countries (5%) and 9 (3.4%) from other Asian, European, and
African countries.

Table 2: Clinical Characteristics of 262 Patients.
Wild type

Mean age at diagnosis (Range)
45 or less
More than 45
Cancer type
Breast Cancer
Ovarian Cancer
Other
Relative of cancer patients
Gender
Female
Male
Family History
Positive
Negative
Ethnicity
Emirates Citizen
Gulf Countries
Arabs
Others
ER, PR, HER2 receptor status
TNBC
Non-TNBC
Unknown#

Mutation
All
n=38 (14.5%)

All

BRCA1
n=18 (6.9%)

n=224

(85.5%)

103
121
(n)
166
17
30
11

46
54
%
(74.1%)
(7.6%)
(13.4%)
(4.9%)

25
13
(n)
20
5
3

65.8
34.2
%
(52.6%)
(13.2%)
(7.9 %)

11
7
(n)
10
3
0

10

(26.3%)

5

%
(55.6%)
(16.7%)
(0.0%)
(27.8%)

214
10

(95.5%)
(4.5%)

34
4

(89.5%)
(10.5%)

17
1

50
174

(22.3%)
(77.7%)

21
17

(55.3%)
(44.7%)

196
7
12
9

(87.5%)
(3.1%)
(5.4%)
(4.0%)

34
3
1
0

21
90
111

(9.4%)
(40.2%)
(49.6%)

7
9
22

BRCA2
n=20 (7.6%)

5

%
(50%)
(10%)
(15%)
(25%)

n=262
46.5
128
134
(n)
(186/262)
(22/262)
(33/262)
(21/262)

(100%)
(21-90)
48.9
51.1
%
(71 %)
(8.4%)
(12.6%)
(8%)

(94.4%)
(5.6%)

17
3

(85%)
(15%)

(248/262)
(14/262)

(94.7%)
(5.3%)

13
5

(72.2%)
(27.8%)

8
12

(40%)
(60%)

(71/262)
(191/262)

(27%)
(73%)

(89.5%)
(7.9%)
(2.6%)
(0.0%)

17
1
0
0

(94.4%)
(5.6 %)
(0.0 %)
(0.0 %)

17
2
1
0

(85%)
(10%)
(5%)
(0%)

(230/262)
(10/262)
(13/262)
(9/262)

(87.8%)
(3.8%)
(5%)
(3.4%)

(18.4%)
(23.7%)
(57.9%)

6
2
10

(33.3%)
(11.1%)
(55.6%)

1
7
12

(5%)
(35%)
(60%)

(28/127)
(99/127)
(133/262)

(22%)
(78%)
(50.7%)

61.1
38.9

14
6
(n)
10
2
3

70
30

24

#Unknown means did not underwent Immunohistochemistry test in SKSH and information is not available. Abbreviations: ER; Estrogen Receptor, PR; Progesterone Receptor, HER2;Human
Epidermal Growth Factor 2 Receptors, TNBC; triple-negative breast cancer, BRCA; Breast Cancer genes
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3.2 Prevalence of Germinal BRCA Mutation
Of total 262, 224 patients and relatives of cancer patients had no mutation in
BRCA genes (85.5%). 38 mutations were identified in BRCA1 and BRCA2 genes
(14.5%, 38/262). 18 out of 38 mutations were in BRCA1 gene (6.9%) and 20 mutations
were in BRCA2 gene (7.6%) as shown in Table.2. All other patients had wild type
BRCA genes with benign or likely benign mutations. All reported mutations revealed
pathogenic mutations except three novel mutations of large exon rearrangements with
one large duplication involving four exons (Exon 3, 5, 6 and 7) with more than
11,658bp in BRCA1 gene and two deletions of either one or more exons in BRCA2
gene. Duplication/ deletions mutations were detected by Deletion/Duplication
Analysis (MLPA) method.
Six different mutations in BRCA1 were identified in 18 patients diagnosed with
BC or/and OC. The most common BRCA1 mutation was frameshift in exon 10:
c.4065_4068delTCAA p. (Asn1355Lysfs*10) which was detected in 5 females and
1 male of one family with a breast cancer history. Same mutation was found in other
6 unrelated patients, 3 with breast cancer and 3 with ovarian cancer. The mean age for
those patients with this type of mutation was 39.7 years (Figure 7 and Table 3).
Another BRCA1 frame shift mutation in exon 10 also c.2704delG (p.
Glu902Asnfs*98) was detected in two members of one family (cousins) with BC
family history. A frame shift mutation in exon 2 c.68_69delAG (p.Glu23Valfs*17)
was detected in a woman with TNBC and positive family history. BRCA1 uncertain
significant mutation c.4186-10G>A was found in intron side of one BC female patient.
13/18 patients with mutation in BRCA1 gene (~72%) had a family history of
breast cancer with age range between 21 and 65 years old (Table 3).
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Out of 38 BRCA positive cases, 20 patients revealed 12 different mutations in
BRCA2 gene. The most common mutation detected in BRCA2 gene was the frame shift
type. 6 BRCA2 mutations revealed in exon 11. Out of 20 patients, 8 (40%) had a
positive family history of breast cancer. The c.771_775delTCAAA (p.Asn257Lysfs)
mutation accounted for 15% of the cases with BRCA2 gene mutation, and
c.2808_2811delACAA (p.Ala938Profs*21) was reported also in other 3 patients
(15%), one with BC and two with OC with average age 49 and positive hormone
receptors. Also, the c.1593dupA (p.Glu532Argfs*3) mutation found in two members
of one family (sister and brother) and one patient all diagnosed with BC (15%). In
addition, two unreported mutations were identified, first a deletion of exon 5 in an
ovarian cancer female patient with a positive family history and another deletion of
four exons (Exons 10-13) in male patient with malignant neoplasm of axillary tail of
left breast (Table 4).

Figure 7: Sequencing chromatogram illustrating the most common mutations in BRCA1 gene c.4065_4068delTCAA
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Table 3: Characteristics of Patients with BRCA1 Gene Mutation

*BRCA1 Gene Mutation

RS ID

Exon
Number

Type of
Mutation

Cases with BRCA1 Gene Mutation, Frequency of
Disease Causing (n=18)
N. of Patients
(n=18)

%

Characteristics
9 with positive family history, 6
members of 1 family with BC, 6
unrelated patients with 3 BC and
3 OC, 3 TNBC, average age 39.7
Positive family history and TNBC
2 members of 1 family (cousins)
with BC, average age 48

c.4065_4068delTCAA
(p.Asn1355Lysfs*10)

rs80357508

10

Frameshift

12

67

c.68_69delAG (p.Glu23Valfs*17)

rs80357914

2

Frameshift

1

6

c.2704delG (p.Glu902Asnfs*98)

rs886040064

10

Frameshift

2

11

3,5,6,7

Frameshift
\Duplication

1

6

Positive Family history, OC
patient, Age ≤ 45

11
20

IVS
Missense

1
1

6
6

TNBC, Age >45
TNBC, Age >45

c.(80+1_81-1)_
(441+1_442-1)dup
(MLPA)
c.4186-10G>A (VUS)
c.5323G>C (p.Glu1775Gln)

rs80358172
rs80357432

*The description of nucleotide sequence is in accordance with HGVS nomenclature. DNA mutations are numerated according to NCBI reference sequence
NM_007300.3 for BRCA1 Bold: most common mutation. Highlighted: Not reported (Novel) mutation. VUS-variant of uncertain significance. MLPAMultiplex ligation-dependent probe amplification analysis. IVS-Intron Variant Sequence.
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Table 4: Characteristics of Patients with BRCA2 Gene Mutation
Cases with BRCA2 Gene Mutation, Frequency of Disease Causing
(n=20)
No. of Patients
*BRCA2 Gene Mutation

RS ID

Exon
Number

c.4124delA (p.Glu1375fs)

rs886040512

11

Frameshift

2

10

c.3649delA (p.Arg1217fs*11)

rs864622134

11

Frameshift

1

5

c.771_775delTCAAA (p.Asn257Lysfs)

rs80359671

9

Frameshift

3

15

c.2808_2811delACAA
(p.Ala938Profs*21)

rs80359351

11

Frameshift

3

15

c.7007G>A (p.Arg2336His)

rs28897743

13

Missense

2

10

5

Frameshift \
Deletion

1

5

Deletion in Exon 5 (MLPA)

Type of
mutation

(n=20)

%

Characteristics
Hormone receptors positive, average age 54, BC
and OC patients
OC patient, age >45
3 members of 1 family (2 sisters and aunty) age ≤
45, all affected with BC
Hormone receptors positive, average age 49, one
BC and two OC patients
Hormone receptors positive, average age 54.5,
Omani BC female and Prostate cancer male
patient
Positive family history, age ≤ 45, OC patient

c.1593dupA (p.Glu532Argfs*3)

rs397507272

10

Frameshift

3

15

**c.4574A>T (p.His1525Leu) (VUS)

rs397507336

11

Missense

1

5

c.2654A>G (p.Asp885Gly)

rs398122750

11

Missense

1

5

2 members of 1 family (brother and sister) and 1
patient, all with BC
Hormone receptors positive BC, Positive family
history, age > 45
BC patient , age ≤ 45

c.4415_4418delAGAA (p.Lys1472fs)

rs397507333

11

Frameshift

1

5

BC patient , age ≤ 45

c.9109C>A( p.Gln3037Lys)

rs397508037

23

Missense
Frameshift \
Deletion

1

5

TNBC, BC patient, age ≤ 45

1

5

Male patient with BC, age ≤ 45

Deletion in Exons 10-13 (MLPA)

10-13

*The description of nucleotide sequence variations is in accordance with HGVS nomenclature. DNA mutations are numerated according to NCBI reference sequence NM_000059.3 for
BRCA2. Bold: most common mutation. Highlighted: Not reported (Novel) mutation. VUS-variant of uncertain significance. MLPA-Multiplex ligation-dependent probe amplification
analysis. ** This mutation was classified as Pathogenic in Varsome and VUS in ClinVar.
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3.3 Association of BRCA Status and TNBC
Out of 262 cases enrolled in this study, 127 cases were tested for TNBC by
immunohistochemistry test (Figure 8).

Figure 8: Immunohistochemical Staining. Representative examples of
immunostaining for the protein markers ER, PR and HER-2. Negative or positive
staining. All the slides were analyzed in x 4 and x 20 microscope objectives.
Brown staining with light blue background refers to positive in ER, PR (B), and
HER2 (A). Light blue background refers to negative (C) for ER, PR, HER-2 as
shown alongside higher magnification.
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Out of total 127 patients, 28 were TNBC (22%). 6 of these TNBC patients
revealed a BRCA1 gene mutations (21.4%) and one patient had a BRCA2 mutation
(3.6%). Other 21 patients didn’t show any mutation either in BRCA1 or BRCA2 genes
(75%). Taken together, BRCA1 mutation carriers were more likely to have TNBC than
those of BRCA2 carriers (Figure 9).

Figure 9: Association of BRCA status and TNBC. Unknown indicated patients who
did not underwent immunohistochemistry test in SKSH.
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3.4 Correlation of BRCA1 Gene Mutation with Different Factors
According to Chen et al. [31], BRCA1 carriers were more likely to have TNBC
than those of BRCA2 carriers or non-BRCA1/2 carriers among patients with breast
cancer [31]. Also, the correlation of BRCA1 gene mutation with different factors
including TNBC, age and familial history was studied. The results showed that patients
with BRCA1 gene mutation is significantly correlated with young age (p < 0.01), and
family history (p < 0.05) while TNBC (p =0.17) alone was not associated with
significant risk (Table 5).

Table 5: Correlation of BRCA1 Gene Mutation with Different Parameters
BRCA1 Mutation
Positive
Factor

No. of
Patients

Negative
%

No. of
Patients

%

Age, years
≤ 45

11

(4.2%)

117

(44.7%)

>45

7

(2.7%)

127

(48.5%)

Family
history of
BC or OC
No

5

(1.9%)

186

(71.0%)

Yes

13

(5.0%)

58

(22.1%)

TNBC
Yes

n

P

262

0.000** (<
0.01)

262

0.02*
(< 0.05)

127
6

(4.7%)

22

(17.3%)

No
2
(1.6%)
97
(76.4%)
Abbreviations: BC: breast cancer; TNBC: triple-negative breast cancer, n: population size.
*Two-sided significance level set at 5%.
**Two-sided significance level set at 1%
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3.5 Novel BRCA1/2 Mutations Among UAE Population in Northern Emirates
In Tables 3 & 4, 15 mutations were found and these mutations had been
reported in different databases such as ClinVar, Breast Cancer Information Core
(BIC), Varsome, AlAmut and/or HGMD2019. Three Novel mutations were detected
by MLPA of a large exon rearrangements first, a duplication of 4 exons (Exon 3,5,6,
and 7) in BRCA1 gene of a 43 years old emirate female who have been diagnosed as
an OC patient with a family history of BC. Other two novel mutations were found in
BRCA2 gene with a deletion of one exon (Exon 5) of a 39 years old female patient
with family history of malignant neoplasm of ovary. Also large deletion of 4 exons
(Exon 10-13) was detected in a 42 years old male patient with malignant neoplasm of
axillary tail of left male breast (Figure 10).

A

Case: a 43 years old emirate female who have been diagnosed as an
OC patient with a family history of BC

Figure 10: Novel BRCA1/2 mutations detected by MLPA analysis workflow in GeneMarker software in this study. Part of an MLPA analysis report
(GeneMarker v3.0.1) of BRCA1 in A and BRCA2 in B and C. The resulting peak ratios are plotted in the ratio plot above, and are reported for each case in
the Report Table to the right. (Upper: Four Duplications, middle: one deletion, and bottom: Four Deletions).
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B

Figure 10: Novel BRCA1/2 mutations detected by MLPA analysis workflow in GeneMarker software in this study. (Continued).
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C

Figure 10: Novel BRCA1/2 mutations detected by MLPA analysis workflow in GeneMarker software in this study. (Continued).
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Chapter 4: Discussion
Cancer poses one of the major health problem challenges worldwide. BRCA1/2
germline mutations are responsible for genetic predisposition and may increase the
risk for breast and ovarian cancer [43]. To date, few studies have been reported on
BRCA associated breast cancer in the Arab world. In the present study, unselected
breast or/and ovarian cancer patients with one of the following high-risk criteria were
eligible for the BRCA mutation analysis: a first- degree relation with a known mutation
in a cancer susceptibility gene, history of TNBC in family member, male breast cancer,
first or second degree relative with breast or ovarian cancer at age ≤45 years.
According to several studies and reports across the globe, prevalence of BRCA
mutations varies widely among different populations. This variation can be attributed
to the effects of founder mutations and environmental factors as well [44-45]. In
Western countries, the genetic testing for breast cancer have become standard clinical
management for selected patients. However, in Arab countries it is still less managed
and genetic testing is not well-established yet. Only few studies reported BRCA
mutations among breast and ovarian cancer in the Eastern and Arab countries.
According to these studies, the BRCA1/2 mutation pooled estimate was about 20%
among patients with both breast and ovarian cancer [12].
To date as per the documented literature, this is the first study in UAE that used
genetic analysis methods to evaluate the prevalence of germline BRCA mutations in
breast and ovarian cancer patients. The analysis was made on patients unselected for
age, family history, gender or the expression of hormonal receptors status. This
retrospective study enrolled patients between July 2015 and August 2020 at Sheikh
Khalifa Specialty Hospital in Ras Al Khaimah, being the leading medical facility for
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the Northern Emirates. The results show that the prevalence of the BRCA1/2 mutation
among the 262 cases enrolled in this study is 14.5% (38/262).
The results of this study were consistent and can be further ascertained with a
recent publication (March 2019) by Abdulrashid et al who report BRCA1/2 prevalence
among HBOC /HBC based on 14 selected studies from different Arab countries. Eight
studies from North Africa (3 Morocco, 2 Algeria, 2 Tunisia, 1 Egypt), four from
Middle East (2 Lebanon, 1 Palestine, 1 Jordan) and two studies from GCC (1 Saudi
Arabia and 1 Qatar) (Table. 1). In Middle East countries, the pooled prevalence of
BRCA mutations was high ~ 28%, followed by the GCC countries with pooled
prevalence ~22%, and the pooled prevalence was 16% in North Africa [18].
Globally, the prevalence of BRCA1/2 mutations was also estimated in an
international publication by Armstrong et al. [37], where a 70 large studies reported
BRCA1 and/or BRCA2 mutation prevalence data in BC patients across the following
12 countries: (33 USA), (11 South Korea), (4 United Kingdom), (4 Spain), (3
Germany), (3 Italy), (2 Canada), (2 Australia) , (2 Russia), (2 France), (1 Japan) and
(3 Israel). The prevalence of germline BRCA mutations enrolled in unselected
population on any basis other than breast cancer was clearly shown in Table.1, where
the highest prevalence was reported in United States study with 15.4% and the lowest
prevalence was reported as 2.7% in a French study [37].
The prevalence of BRCA1 and BRCA2 in this study population were 6.9% and
7.6% respectively. Data from Arab region studies showed that BRCA2 is the most
common type mutation among HOBC patients with an estimated pooled prevalence of
17% [18]. Likewise, among Asian populations BRCA2 mutations are more common.
Western population showed a different pattern, where BRCA1 mutations were more
common. One study on Saudi patients reported the frequency of BRCA1 mutations as

39
10.7% [27]. BRCA mutations prevalence could vary widely within demographic
groups and over countries
In this study, 18 mutations were reported of both BRCA genes in 38 breast
and/or ovarian cancer patients. In addition to sequencing method, MLPA was also
performed for all patients’ samples. The results showed a number of rearrangement of
BRCA gene exons either deletion or duplication of one or more exons in BRCA1/2
genes. Most of these mutations were frameshift deletions (10%) in BRCA2,
duplications (5.6%) in BRCA1 gene. Some common BRCA1/2 mutations were found
and reported previously in the GCC, Arab Countries and world populations. For
example, the most abundant BRCA1 mutation in this study c.4065_4068delTCAA
(p.Asn1355Lysfs*10) was found twelve times in eight female patients and one male
patient with strong family history of breast cancer and also this mutation is prevalent
in GCC , Middle East, Europe populations [14, 36].
Another mutation was found in BRCA1 gene, c.66_67AG (p.Glu23Valfs*17)
which was detected in a migrant woman worker from India with breast cancer. Also,
this mutation accounted for the 30.4% of the BRCA1 mutations and is common in
Spanish and Ashkenazi Jewish populations. Ovarian cancer patients are more likely to
carry this type of mutation [36].
Three most common pathogenic frameshift mutations found in BRCA2 gene
are c.1593dupA (p.Glu532Argfs*3), c.771_775delTCAAA (p.Asn257Lysfs) and
c.2808_2811delACAA (p.Ala938Profs*21). All these mutations were detected in
emirate families with breast cancer history. First c.1593dupA (p.Glu532Argfs*3), was
found in one sister and brother, the second c.771_775delTCAAA (p.Asn257Lysfs) in
two sisters of another family and the third mutation c.2808_2811delACAA
(p.Ala938Profs*21) found to be one of the common mutations in GCC populations
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[31]. A missense mutation c.7007G>A (p.Arg2336His) was found twice in Omani
female and male cancer patients and this mutation has been reported in populations of
Middle East , Saudi Arabia and Qatar [14][36]. According to a review by Rahman, S.,
and Zayed, H. [14], ClinVar reports confirmed the pathogenicity for BRCA2 c.7007G
> A and that it can cause disease. Also, this mutation was found in Hong Kong [14].
Triple negative breast cancer is aggressive molecular subtype among other
breast cancer cases because it lacks ER, PR and expression of HER2 receptors. Thus,
no validated molecular targets are available for the treatment and therefore considered
a high-risk breast cancer with overall poor prognosis. Of all breast cancers, TNBC
accounts for about 15%. Reports showed that TNBCs are the predominant cancer
subtype with a germline BRCA mutation in which the prevalence of the BRCA
mutation is 10 to 30% [46-48]. BRCA1 mutation shown also to occur more frequently
at younger age [23]. In this study, BRCA1/2 mutation in TNBC patients was evaluated.
Among all 127 patients who underwent immunohistochemistry staining in Pathology
Department of Sheikh Khalifa Specialty Hospital, 28 patients (22%) were identified
with immunohistologically confirmed invasive, ER, PR, and HER2 negative BC.
A total of 7 (25%) BRCA mutations were identified in 28 patients who had TNBC.
In the current screening, the prevalence of the BRCA1 germline mutation was about
21.4% (6/28), and the prevalence of the BRCA2 germline mutation was about 3.5%
(1/28). These data revealed that the prevalence of BRCA1 mutations is more common
than BRCA2 in TNBC patients, and BRCA1 mutation is found more common among
TNBC patients but not significantly correlated with the BRCA1 mutation.
These findings are consistent with the data from international studies
demonstrating that BRCA1 gene mutation were more common (85.7%) than BRCA2
gene mutation (14.3%) in TNBC [36]. Furthermore, literature revealed that TNBC is
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the predominant molecular profile in patients with a germline BRCA1 mutations [4950]. Several studies have evaluated the prevalence of BRCA1 mutations in patients
with TNBC. Reports showed that the prevalence of BRCA1 mutations in TNBC
patients varies between populations and from one study to another. Most studies
included patient populations selected for young age at diagnosis (< 50 years) and
reported a prevalence ranging from 7.6 to 23% [51-54]. While other studies evaluated
the frequency of BRCA1 mutations in unselected TNBC patient populations. The
BRCA1 mutation frequency was 6.5% when unselected women with TNBC were
evaluated [55]. When selected by age, the frequency of BRCA1 mutations was 2.8%
in patients diagnosed at age ≥ 50 years [55]. One study showed that BRCA1 mutations
were detected in 9% of unselected TNBC patients and in 4.8% of women diagnosed at
age ≥ 50 years [56]. In one large study of unselected TNBC patients (n = 1824), the
prevalence of BRCA1 mutation was 8.5%. For the 50–59 age group, the prevalence
was 7.4% [57]. In this study 21.4% (6/28) of TNBC patients, unselected for age and
family history, were found to carry BRCA1 mutation. These findings are with the
agreement with previous reports for Asian populations [44-45, 58-59], where BRCA1mutated tumors were ER- or PR-negative and had a higher histological grade, but
exhibited less medullary carcinoma compared to the Western population [25]. Studies
have shown that

TNBC

with

BRCA1

has

a unique morphology and

immunohistochemical phenotype that explains the susceptibility of breast cancer
women with germline BRCA1 mutations to be triple negative [30]. TNBC with family
history may influence the BRCA mutation. Although several studies have evaluated
the prognostic role of the BRCA1/2 mutation in patients with TNBC, these studies have
shown inconclusive results. The present study is a small scale screening analysis and
not all patients underwent immunohistochemistry. Therefore, a possible association
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between TNBC, BRCA carriers, and positive family history was not made involving
all breast cancer patients enrolled in this study. Thus, a conclusion needs more data
collection and further investigation.
Three novel large exons rearrangement of both BRCA1 and BRCA2 genes using
MLPA were found in two female ovarian cancer patients with strong family history
and one breast cancer male. One large BRCA1 genomic rearrangements duplication in
exon 3, 5, 6 and 7 (c.(80+1_81-1)_(441+1_442-1) dup) was detected in a 43 years old
female patient with ovarian cancer and considered a novel mutation as it was not
reported in any database yet. As reviewed by Rahman and Zayed [14], the genomic
rearrangement in BRCA1 that was found in a study of 43 Omani BC female patients
which only exon 3,5,11,13 and 20 were tested by direct Sequencing and MLPA and
they identified four large genomic rearrangement were revealed: two duplications and
two deletions in exons 1 and 2 [14].
In BRCA2, one case with a deletion of exon 5 was detected in ovarian cancer
female patient and there is no available data of the contribution of BRCA2 mutations
located on exon 5. Another large deletion of four exons in BRCA2 gene was identified
in breast cancer young male patient and similar to this mutation (deletion of 3 exons
10-12) was reported once in the literature [60].
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Chapter 5: Conclusion and Future Recommendations
In conclusion, this study provides a baseline information on the prevalence of
BRCA mutation in hospital based population in northern emirates. The current findings
indicate that 14.5% of unselected patients enrolled in this study carried BRCA
mutations. The present data provide an evident contribution of BRCA1 and BRCA2
mutation in patients of breast and ovarian cancer. One limitation of this study is the
low number of patients who underwent TNBC testing. Furthermore, the results suggest
to collect more data regarding the status of TNBC and BRCA mutations to make a
conclusive data whether TNBC could be an effective threshold for BRCA genetic test
and whether to be considered in genetic testing guidelines in UAE in the future.
Moreover, this study could be extended further by investigating the possible
association between patients with positive BRCA mutations and the clinical
histopathology of the cancer.
To date, there is no large scale study conducted in Arab countries for BRCA
mutations including UAE. Therefore, it is important to conduct a large scale
investigation to better understand the contribution and the frequency of BRCA
mutations in patients with TNBC. This will contribute to genetic counseling for
mutation carriers, offer better disease management and will definitely play an
important role in establishing local diagnostic frame for genetic testing.

.
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